Intellia Therapeutics (NASDAQ:NTLA) Releases Earnings Results, Misses Expectations By $0.03 EPS

Intellia Therapeutics (NASDAQ:NTLAGet Rating) released its earnings results on Thursday. The company reported ($1.33) EPS for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.03), Briefing.com reports. The company had revenue of $14.00 million for the quarter, compared to analysts’ expectations of $9.50 million. Intellia Therapeutics had a negative return on equity of 41.00% and a negative net margin of 973.48%. The firm’s revenue for the quarter was up 115.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.01) EPS.

Intellia Therapeutics Price Performance

Shares of NTLA stock traded down $2.11 during trading hours on Friday, hitting $63.32. The company had a trading volume of 2,004,366 shares, compared to its average volume of 1,221,357. The company’s fifty day moving average is $55.42 and its 200 day moving average is $64.22. Intellia Therapeutics has a fifty-two week low of $37.08 and a fifty-two week high of $180.59. The stock has a market capitalization of $4.80 billion, a PE ratio of -12.59 and a beta of 2.00.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. JMP Securities cut their target price on shares of Intellia Therapeutics from $165.00 to $110.00 in a research note on Monday, May 9th. Credit Suisse Group assumed coverage on shares of Intellia Therapeutics in a research note on Thursday, April 28th. They set an “outperform” rating and a $100.00 price objective for the company. Chardan Capital dropped their price objective on shares of Intellia Therapeutics from $172.00 to $146.00 and set a “buy” rating for the company in a research note on Friday. Bank of America assumed coverage on shares of Intellia Therapeutics in a research note on Thursday, June 16th. They set a “buy” rating and a $70.00 price objective for the company. Finally, SVB Leerink dropped their price objective on shares of Intellia Therapeutics from $155.00 to $152.00 and set an “outperform” rating for the company in a research note on Friday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $133.78.

Hedge Funds Weigh In On Intellia Therapeutics

Several large investors have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company lifted its holdings in shares of Intellia Therapeutics by 42.2% in the 1st quarter. The Manufacturers Life Insurance Company now owns 49,800 shares of the company’s stock worth $3,609,000 after acquiring an additional 14,781 shares during the last quarter. BNP Paribas Arbitrage SA lifted its holdings in shares of Intellia Therapeutics by 62.2% in the 1st quarter. BNP Paribas Arbitrage SA now owns 59,941 shares of the company’s stock worth $4,356,000 after acquiring an additional 22,983 shares during the last quarter. Walleye Capital LLC lifted its holdings in shares of Intellia Therapeutics by 585.1% in the 1st quarter. Walleye Capital LLC now owns 50,521 shares of the company’s stock worth $3,671,000 after acquiring an additional 43,147 shares during the last quarter. Point72 Hong Kong Ltd acquired a new position in shares of Intellia Therapeutics in the 1st quarter worth approximately $165,000. Finally, Polar Capital Holdings Plc acquired a new stake in Intellia Therapeutics during the 1st quarter worth approximately $18,713,000. 85.89% of the stock is currently owned by institutional investors and hedge funds.

About Intellia Therapeutics

(Get Rating)

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency.

See Also

Earnings History for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.